Janel Long-Boyle, PharmD, PhD
Professor
Clinical Pharmacy
School of Pharmacy

Specifically, Dr. Boyle studies how covariates such as age, renal function, or genetic variants involved in drug metabolism or distribution may influence drug clearance in the pediatric HCT population.

• Diagnosing and Grading of Sinusoidal Obstructive Syndrome after Hematopoietic Stem Cell Transplant of Children, Adolescent and Young Adults treated in a Pediatric Institution with Pediatric Protocols.
  Transplantation and cellular therapy 2024 Salinas Cisneros G, Dvorak CC, Long-Boyle J, Kharbanda S, Shimano KA, Melton A, Chu J, Winestone LE, Dara J, Huang JN, Hermiston ML, Zinter M, Higham CS
• Maximum a posteriori Bayesian methods out-perform non-compartmental analysis for busulfan precision dosing.
  Journal of pharmacokinetics and pharmacodynamics 2024 Hughes JH, Long-Boyle J, Keizer RJ
• Effect of Clemastine on Neurophysiological Outcomes in an Ovine Model of Neonatal Hypoxic-Ischemic Encephalopathy.
  Children (Basel, Switzerland) 2023 Mike JK, White Y, Hutchings RS, Vento C, Ha J, Iranmahboub A, Manzoor H, Gunewardena A, Cheah C, Wang A, Goudy BD, Lakshminrusimha S, Long-Boyle J, Fineman JR, Ferriero DM, Maltepe E
• Busulfan and subsequent malignancy: An evidence-based risk assessment.
  Pediatric blood & cancer 2023 Long-Boyle JR, Kohn DB, Shah AJ, Spencer SM, Sevilla J, Booth C, López Lorenzo JL, Nicoletti E, Shah A, Reatz M, Matos J, Schwartz JD
• Perinatal Azithromycin Provides Limited Neuroprotection in an Ovine Model of Neonatal Hypoxic-Ischemic Encephalopathy.
  Stroke 2023 Mike JK, White Y, Hutchings RS, Vento C, Ha J, Manzoor H, Lee D, Losser C, Arellano K, Vanhatalo O, Seifert E, Gunewardena A, Wen B, Wang L, Wang A, Goudy BD, Vali P, Lakshminrusimha S, Gobburu JVS, …
• Lentiviral Gene Therapy for Artemis-Deficient SCID.
  The New England journal of medicine 2022 Cowan MJ, Yu J, Facchino J, Fraser-Browne C, Sanford U, Kawahara M, Dara J, Long-Boyle J, Oh J, Chan W, Chag S, Broderick L, Chellapandian D, Decaluwe H, Golski C, Hu D, Kuo CY, Miller HK, Petrovic A,…
• Prospective Validation and Refinement of a Population Pharmacokinetic Model of Fludarabine in Children and Young Adults Undergoing Hematopoietic Cell Transplantation.
  Pharmaceutics 2022 Brooks JT, Solans BP, Lu Y, Kharbanda S, Dvorak CC, Lalefar N, Long S, Gupta AO, Horn B, Lamba JK, Huang L, Apsel-Winger B, Keizer RJ, Savic R, Long-Boyle J
• Quantification of N, N' N"-triethylenethiophosphoramide, N, N"-triethylenephosphoramide, cyclophosphamide, and 4-hydroxy-cyclophosphamide in microvolume human plasma to support neonatal and pediatric drug studies.
  Journal of chromatography open 2022 Huang L, Winger BA, Cheah V, Gingrich D, Marzan F, Lu Y, Cooper JC, Aweeka F, Long-Boyle J
• Defining Longer-Term Outcomes in an Ovine Model of Moderate Perinatal Hypoxia-Ischemia.
  Developmental neuroscience 2022 Mike JK, Wu KY, White Y, Pathipati P, Ndjamen B, Hutchings RS, Losser C, Vento C, Arellano K, Vanhatalo O, Ostrin S, Windsor C, Ha J, Alhassen Z, Goudy BD, Vali P, Lakshminrusimha S, Gobburu JVS, Long…
• Population Pharmacokinetics of Melphalan for Pediatric Patients Undergoing Hematopoietic Cell Transplantation.
  Journal of clinical pharmacology 2022 Li S, Dvorak CC, Lu Y, Chan D, Gobburu JVS, Long-Boyle J, Apsel Winger B
• Association Between the Magnitude of Intravenous Busulfan Exposure and Development of Hepatic Veno-Occlusive Disease in Children and Young Adults Undergoing Myeloablative Allogeneic Hematopoietic Cell Transplantation.
  Transplantation and cellular therapy 2022 Bognàr T, Bartelink IH, Egberts TCG, Rademaker CMA, Versluys AB, Slatter MA, Kletzel M, Nath CE, Cuvelier GDE, Savic RM, Dvorak C, Long-Boyle JR, Cowan MJ, Bittencourt H, Bredius RGM, Güngör T, Shaw …
• Population Pharmacokinetic Model Development of Tacrolimus in Pediatric and Young Adult Patients Undergoing Hematopoietic Cell Transplantation.
  Frontiers in pharmacology 2021 Brooks JT, Keizer RJ, Long-Boyle JR, Kharbanda S, Dvorak CC, Friend BD
• Busulfan dose Recommendation in Inherited Metabolic Disorders: Population Pharmacokinetic Analysis.
  Transplantation and cellular therapy 2021 Takahashi T, Illamola SM, Jennissen CA, Long SE, Lund TC, Orchard PJ, Gupta AO, Long-Boyle JR
• 5-Azacytidine depletes HSCs and synergizes with an anti-CD117 antibody to augment donor engraftment in immunocompetent mice.
  Blood advances 2021 Bankova AK, Pang WW, Velasco BJ, Long-Boyle JR, Shizuru JA
• A Guidance for Concomitant Drug Reconciliation Prior to Allogeneic Hematopoietic Cell Transplantation in Children and Young Adults.
  Frontiers in pediatrics 2021 Apsel Winger B, Long SE, Brooks J, Gupta AO, Dvorak CC, Long-Boyle JR
• Transplant-associated thrombotic microangiopathy in pediatric patients: pre-HSCT risk stratification and prophylaxis.
  Blood advances 2021 Higham CS, Collins G, Shimano KA, Melton A, Kharbanda S, Winestone LE, Huang JN, Dara J, Long-Boyle JR, Dvorak CC
• The Relationship Between Busulfan Exposure and Achievement of Sustained Donor Myeloid Chimerism in Patients with Non-Malignant Disorders.
  Transplantation and cellular therapy 2020 Apsel Winger B, Shukla P, Kharbanda S, Keizer RJ, Goswami S, Cowan MJ, Dvorak CC, Long-Boyle J
• Prescribing Prevalence of Medications With Potential Genotype-Guided Dosing in Pediatric Patients.
  JAMA network open 2020 Ramsey LB, Ong HH, Schildcrout JS, Shi Y, Tang LA, Hicks JK, El Rouby N, Cavallari LH, Tuteja S, Aquilante CL, Beitelshees AL, Lemkin DL, Blake KV, Williams H, Cimino JJ, Davis BH, Limdi NA, Empey PE,…
• Lower Exposure to Busulfan Allows for Stable Engraftment of Donor Hematopoietic Stem Cells in Children with Mucopolysaccharidosis Type I: A Case Report of Four Patients.
  International journal of molecular sciences 2020 Shukla P, Dvorak CC, Long-Boyle J, Kharbanda S
• Assessment of a Model-Informed Precision Dosing Platform Use in Routine Clinical Care for Personalized Busulfan Therapy in the Pediatric Hematopoietic Cell Transplantation (HCT) Population.
  Frontiers in pharmacology 2020 Shukla P, Goswami S, Keizer RJ, Winger BA, Kharbanda S, Dvorak CC, Long-Boyle J
• Reduced Toxicity Conditioning for Nonmalignant Hematopoietic Cell Transplants.
  Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2020 Contreras CF, Long-Boyle JR, Shimano KA, Melton A, Kharbanda S, Dara J, Higham C, Huang JN, Cowan MJ, Dvorak CC
• Population Pharmacokinetics of Vemurafenib in Children With Recurrent/Refractory BRAF Gene V600E-Mutant Astrocytomas.
  Journal of clinical pharmacology 2020 Wang H, Long-Boyle J, Winger BA, Nicolaides T, Mueller S, Prados M, Ivaturi V
• Phase I study of vemurafenib in children with recurrent or progressive BRAFV600E mutant brain tumors: Pacific Pediatric Neuro-Oncology Consortium study (PNOC-002).
  Oncotarget 2020 Nicolaides T, Nazemi KJ, Crawford J, Kilburn L, Minturn J, Gajjar A, Gauvain K, Leary S, Dhall G, Aboian M, Robinson G, Long-Boyle J, Wang H, Molinaro AM, Mueller S, Prados M
• Lentiviral Gene Therapy Combined with Low-Dose Busulfan in Infants with SCID-X1.
  The New England journal of medicine 2019 Mamcarz E, Zhou S, Lockey T, Abdelsamed H, Cross SJ, Kang G, Ma Z, Condori J, Dowdy J, Triplett B, Li C, Maron G, Aldave Becerra JC, Church JA, Dokmeci E, Love JT, da Matta Ain AC, van der Watt H, …
• Population Pharmacokinetics of Clofarabine as Part of Pretransplantation Conditioning in Pediatric Subjects before Hematopoietic Cell Transplantation.
  Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2019 Wang H, Jones AK, Dvorak CC, Huang L, Orchard P, Ivaturi V, Long-Boyle J
• Low Exposure Busulfan Conditioning to Achieve Sufficient Multilineage Chimerism in Patients with Severe Combined Immunodeficiency.
  Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2019 Dvorak CC, Long-Boyle J, Dara J, Melton A, Shimano KA, Huang JN, Puck JM, Dorsey MJ, Facchino J, Chang CK, Cowan MJ
• Determination of melphalan in human plasma by UPLC-UV method.
  Cancer chemotherapy and pharmacology 2019 Huang L, Cheah V, Chan D, Marzan F, Dvorak CC, Aweeka FT, Long-Boyle J
• Correction: Preservation of myocardial contractility during acute hypoxia with OMX-CV, a novel oxygen delivery biotherapeutic.
  PLoS biology 2019 Boehme J, Le Moan N, Kameny RJ, Loucks A, Johengen MJ, Lesneski AL, Gong W, Goudy BD, Davis T, Tanaka K, Davis A, He Y, Long-Boyle J, Ivaturi V, Gobburu JVS, Winger JA, Cary SP, Datar SA, Fineman JR, …
• A Practical First Step Using Needs Assessment and a Survey Approach to Implementing a Clinical Pharmacogenomics Consult Service.
  Journal of the American College of Clinical Pharmacy : JACCP 2018 Zakinova A, Long-Boyle JR, French D, Croci R, Wilson L, Phillips KA, Kroetz DL, Shin J, Tamraz B
• Preservation of myocardial contractility during acute hypoxia with OMX-CV, a novel oxygen delivery biotherapeutic.
  PLoS biology 2018 Boehme J, Le Moan N, Kameny RJ, Loucks A, Johengen MJ, Lesneski AL, Gong W, Goudy BD, Davis T, Tanaka K, Davis A, He Y, Long-Boyle J, Ivaturi V, Gobburu JVS, Winger JA, Cary SP, Datar SA, Fineman JR, …
• Sirolimus for management of complex vascular anomalies - A proposed dosing regimen for very young infants.
  International journal of pediatric otorhinolaryngology 2017 Czechowicz JA, Long-Boyle JR, Rosbe KW, Mathes EF, Frieden IJ, Shimano KA
• Randomised placebo-controlled safety and tolerability trial of FK506 (tacrolimus) for pulmonary arterial hypertension.
  The European respiratory journal 2017 Spiekerkoetter E, Sung YK, Sudheendra D, Scott V, Del Rosario P, Bill M, Haddad F, Long-Boyle J, Hedlin H, Zamanian RT
• Opening Marrow Niches in Patients Undergoing Autologous Hematopoietic Stem Cell Gene Therapy.
  Hematology/oncology clinics of North America 2017 Cowan MJ, Dvorak CC, Long-Boyle J
• Pharmacokinetics and Model-Based Dosing to Optimize Fludarabine Therapy in Pediatric Hematopoietic Cell Transplant Recipients.
  Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2017 Ivaturi V, Dvorak CC, Chan D, Liu T, Cowan MJ, Wahlstrom J, Stricherz M, Jennissen C, Orchard PJ, Tolar J, Pai SY, Huang L, Aweeka F, Long-Boyle J
• Phase 1 study of sirolimus in combination with oral cyclophosphamide and topotecan in children and young adults with relapsed and refractory solid tumors.
  Oncotarget 2017 Vo KT, Karski EE, Nasholm NM, Allen S, Hollinger F, Gustafson WC, Long-Boyle JR, Shiboski S, Matthay KK, DuBois SG
• Busulfan after HSCT in children and young adults - Authors' reply.
  The Lancet. Haematology 2017 Bartelink IH, Lalmohamed A, Long-Boyle JR, Boelens JJ
• Association of busulfan exposure with survival and toxicity after haemopoietic cell transplantation in children and young adults: a multicentre, retrospective cohort analysis.
  The Lancet. Haematology 2016 Bartelink IH, Lalmohamed A, van Reij EM, Dvorak CC, Savic RM, Zwaveling J, Bredius RG, Egberts AC, Bierings M, Kletzel M, Shaw PJ, Nath CE, Hempel G, Ansari M, Krajinovic M, Théorêt Y, Duval M, Keizer…
• Pharmacokinetics, Pharmacodynamics, and Pharmacogenomics of Immunosuppressants in Allogeneic Hematopoietic Cell Transplantation: Part II.
  Clinical pharmacokinetics 2016 McCune JS, Bemer MJ, Long-Boyle J
• Personalized fludarabine dosing to reduce nonrelapse mortality in hematopoietic stem-cell transplant recipients receiving reduced intensity conditioning.
  Translational research : the journal of laboratory and clinical medicine 2016 Sanghavi K, Wiseman A, Kirstein MN, Cao Q, Brundage R, Jensen K, Rogosheske J, Kurtzweil A, Long-Boyle J, Wagner J, Warlick ED, Brunstein CG, Weisdorf DJ, Jacobson PA
• Low-Dose FK506 (Tacrolimus) in End-Stage Pulmonary Arterial Hypertension.
  American journal of respiratory and critical care medicine 2015 Spiekerkoetter E, Sung YK, Sudheendra D, Bill M, Aldred MA, van de Veerdonk MC, Vonk Noordegraaf A, Long-Boyle J, Dash R, Yang PC, Lawrie A, Swift AJ, Rabinovitch M, Zamanian RT
• Population pharmacokinetics of busulfan in pediatric and young adult patients undergoing hematopoietic cell transplant: a model-based dosing algorithm for personalized therapy and implementation into routine clinical use.
  Therapeutic drug monitoring 2015 Long-Boyle JR, Savic R, Yan S, Bartelink I, Musick L, French D, Law J, Horn B, Cowan MJ, Dvorak CC
• Predicting Pediatric Drug Disposition-Present and Future Directions of Pediatric Physiologically-Based Pharmacokinetics.
  Drug metabolism letters 2015 Miyagi SJ, Long-Boyle JR
• Simultaneous determination of fludarabine and clofarabine in human plasma by LC-MS/MS.
  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2014 Huang L, Lizak P, Dvorak CC, Aweeka F, Long-Boyle J
• Development and validation of a liquid chromatography-tandem mass spectrometry assay to quantify plasma busulfan.
  Therapeutic drug monitoring 2014 French D, Sujishi KK, Long-Boyle JR, Ritchie JC
• Primary Immune Deficiency Treatment Consortium (PIDTC) report.
  The Journal of allergy and clinical immunology 2013 Griffith LM, Cowan MJ, Notarangelo LD, Kohn DB, Puck JM, Pai SY, Ballard B, Bauer SC, Bleesing JJ, Boyle M, Brower A, Buckley RH, van der Burg M, Burroughs LM, Candotti F, Cant AJ, Chatila T, …
• Effect of weight and maturation on busulfan clearance in infants and small children undergoing hematopoietic cell transplantation.
  Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2013 Savic RM, Cowan MJ, Dvorak CC, Pai SY, Pereira L, Bartelink IH, Boelens JJ, Bredius RG, Wynn RF, Cuvelier GD, Shaw PJ, Slatter MA, Long-Boyle J
• Determination of intracellular fludarabine triphosphate in human peripheral blood mononuclear cells by LC-MS/MS.
  Journal of pharmaceutical and biomedical analysis 2013 Huang L, Lizak P, Aweeka F, Long-Boyle J
• Population pharmacokinetics of unbound mycophenolic acid in adult allogeneic haematopoietic cell transplantation: effect of pharmacogenetic factors.
  British journal of clinical pharmacology 2013 Frymoyer A, Verotta D, Jacobson P, Long-Boyle J
• Busulfan, fludarabine, and alemtuzumab as a reduced toxicity regimen for children with malignant and nonmalignant diseases improves engraftment and graft-versus-host disease without delaying immune reconstitution.
  Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2012 Law J, Cowan MJ, Dvorak CC, Musick L, Long-Boyle JR, Baxter-Lowe LA, Horn B
• Population pharmacokinetics of unbound mycophenolic acid in pediatric and young adult patients undergoing allogeneic hematopoietic cell transplantation.
  Journal of clinical pharmacology 2011 Kim H, Long-Boyle J, Rydholm N, Orchard PJ, Tolar J, Smith AR, Jacobson P, Brundage R
• Pharmacokinetics of clofarabine in patients with high-risk inherited metabolic disorders undergoing brain-sparing hematopoietic cell transplantation.
  Journal of clinical pharmacology 2010 Long-Boyle J, Huang J, Rydholm N, Smith A, Orchard P, Tolar J, Jacobson P
• High fludarabine exposure and relationship with treatment-related mortality after nonmyeloablative hematopoietic cell transplantation.
  Bone marrow transplantation 2010 Long-Boyle JR, Green KG, Brunstein CG, Cao Q, Rogosheske J, Weisdorf DJ, Miller JS, Wagner JE, McGlave PB, Jacobson PA
• Comparison of two mycophenolate mofetil dosing regimens after hematopoietic cell transplantation.
  Bone marrow transplantation 2009 Jacobson P, El-Massah SF, Rogosheske J, Kerr A, Long-Boyle J, DeFor T, Jennissen C, Brunstein C, Wagner J, Tomblyn M, Weisdorf D
• High unbound mycophenolic acid concentrations in a hematopoietic cell transplantation patient with sepsis and renal and hepatic dysfunction.
  Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2005 Jacobson P, Long J, Rogosheske J, Brunstein C, Weisdorf D
• Relationship of mycophenolic acid exposure to clinical outcome after hematopoietic cell transplantation.
  Clinical pharmacology and therapeutics 2005 Jacobson P, Rogosheske J, Barker JN, Green K, Ng J, Weisdorf D, Tan Y, Long J, Remmel R, Sawchuk R, McGlave P
• Platelet factor 4 enhances generation of activated protein C in vitro and in vivo.
  Blood 2003 Slungaard A, Fernandez JA, Griffin JH, Key NS, Long JR, Piegors DJ, Lentz SR